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ABSTRACT
Prevalence rates of epilepsy in individuals with intellectual disability (ID) are much
higher than in the general population. Although antiepileptic drug (AED) therapy is considered
the first line of treatment, a significant number of individuals on AEDs still do not achieve total
seizure control. Further, many individuals experience side effects (SE) from long-term AED use.
The assessment of AED SE in individuals with ID and epilepsy is an important aspect of
treatment. The present study focused on the Scale for the Evaluation and Identification of
Seizures, Epilepsy, and Anticonvulsant Side Effects-B (SEIZES-B), developed to assess SE from
AED use in adults with ID and epilepsy. The purpose of this study was two-fold. First, the
psychometric properties of the SEIZES-B were investigated. Interrater reliability of direct
observations was explored using a licensed epileptologist and registered nurse as informants.
Interrater reliability between observers was poor. The SEIZES-B was then compared to the
epileptologists’ direct observation rating to provide an estimate of convergent validity.
Correlational analyses were low and non-significant. Second, 45 participants were compared
across three groups (those with epilepsy taking AEDs, those with a diagnosis of epilepsy not
taking AEDs, and those without epilepsy taking antipsychotic medications) on SE profiles of the
SEIZES-B. Significant differences were not found across the groups. Results and implications of
these data are discussed.
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INTRODCTION
Individuals with epilepsy and intellectual disabilities (ID) often experience side effects
(SE) from antiepileptic drug (AED) use. Despite the availability of newer AEDs associated with
less severe SE, individuals with ID remain susceptible (Ettinger, Barr, & Solomon, 2001).
Traditional standards for assessing SE in the general population often rely on self-report.
Individuals with ID, however, often have communication deficits making self-report instruments
inappropriate for this population. The first goal of this study further investigated the
psychometric properties of The Scale for the Evaluation and Identification of Seizures, Epilepsy,
and Anticonvulsant Side Effects-B (SEIZES-B), for the evaluation and identification of AED SE
using third-party ratings. The second goal of this study examined SE profiles of the SEIZES-B of
those taking AEDs, those not taking AEDs, and those without epilepsy taking antipsychotic
medications. This study represents an essential step towards validating the use of this scale in the
ID population and may facilitate its use in identifying SE from AED use. A brief review of ID,
seizures and epilepsy, and those with comorbid ID and epilepsy is discussed.
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INTELLECTUAL DISABILITY
Definition and Classification
Prior to the nineteenth century there was little uniformity worldwide in the description
and classification of ID. Although ID has always been present, its definition is socially and
politically driven (Patton & Jones, 1994; Scheerenberger, 1983). The official classification of ID
was formulated by two organizations, the American Association on Mental Retardation (AAMR;
1992) and the American Psychiatric Association (APA; 2000). The AAMR and APA
classification system include three essential features of ID, including: 1) deficits in intellectual
functioning; 2) concurrent deficits in adaptive functioning; and 3) onset before age 18. While
these classification systems are similar on the basis of criteria used to determine ID, they differ
in their application. For example, the AAMR definition is intended to facilitate inclusive
education, supported or competitive employment, and supported living (MacMillian, Gresham,
& Siperstein, 1995), whereas the Diagnostic and Statistical Manual, Fourth Edition Text
Revision (DSM-IV-TR) specifies severity levels of ID based on standardized, individually
administered intelligence tests (APA, 2000).
Assessment of Intellectual Functioning
General intellectual functioning is measured by the intelligence quotient (IQ; Eysenck,
1962), obtained by objective, standardized, individually administered intelligence tests (e.g.,
Standford-Binet, Wechsler Intelligence Scales; APA, 2000). In 1905, the Binet-Simon Individual
Tests of Intelligence was the first intelligence test that assessed judgment, comprehension,
reasoning, as well as, distinguished between varying degrees of ID (i.e., idiocy, imbecility, and
moronity; Eysenck, 1962). Currently, sub-average intellectual functioning is defined as an IQ
score of approximately 70 or below, which are two standard deviations below the population
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mean (Biasini, Grupe, Huffman, & Bray, 2001). Until 1960, sub-average intelligence was
considered the sole criteria for ID classification according to the AAMR (AAMR, 1992). In
1961, the AAMR redefined ID to also include limitations in adaptive functioning and onset
before age 18 (Patton & Jones, 1994).
One of the major problems in applying conventional intelligence tests to the ID
population is that these individuals may be influenced by additional deficits such as lack of
motivation to comply with testing, thus making it difficult or impossible to use the available
instruments and testing protocols (Beirne-Smith, Ittenbach, & Patton, 1994). Another criticism in
applying conventional intelligence tests to this population is that intelligence tests measure a
limited range of intellectual abilities. There are other abilities such as adaptive behavior, which
rely on everyday (i.e., social and practical) intelligence that cannot be estimated accurately by
standardized intelligence tests (Patton & Jones, 1994). To this end, adaptive functioning has
become an important and necessary accessory to any diagnostic standard for ID (Greenspan,
Switzsky, & Granfield, 1996).
Assessment of Adaptive Functioning
Assessment of adaptive behavior focuses on how well an individual can function
independently and meet the social and practical demands imposed on the individual by their
culture (Beirne-Smith, Patton, & Ittenbach, 1994). According to the DSM-IV-TR, criteria is met
when deficits in at least two of the following 10 areas has been demonstrated: communication,
social skills, self-care, home living, use of community resources, self-direction, health and
safety, functional academics, leisure, and work (APA, 2000). Although there are numerous
adaptive behavior scales, the most commonly used scale is the Vineland Adaptive Behavior
Scales (VABS; Sparrow, Balla, & Cicchetti, 1984). The VABS was designed to assess
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handicapped and non-handicapped persons from birth to adulthood in their personal and social
functioning. The VABS is organized around four behavior domains: communication, daily living
skills, socialization, and motor skills (Doll, 1953). The utility of adaptive instruments for
identifying persons with ID has been debated because domains such as leisure, work, and use of
community resources are difficult to define and measure (Zigler, Balla, & Hodapp, 1984). On the
other hand, adaptive scales used in conjunction with other standardized assessments provide
valuable information regarding communication, social skills, and daily living which can be
useful in treatment planning (Greenspan, Switzsky, & Granfield, 1996).
The last criterion for a diagnosis of ID is onset before age 18 (AAMR, 1992; APA,
2000). For example, many chromosomal abnormalities associated with more severe levels of ID
such fragile X syndrome or Down’s syndrome is diagnosed during pregnancy or infancy
(Dykens, Hodapp, & Fincucane, 2000). Milder levels of ID tend to be diagnosed in early
childhood whereas ID with an unknown etiology is usually diagnosed later in childhood
(Alexander, 1998).
Characteristics of Intellectual Disability
The current criteria used to differentiate severity levels of ID are associated with ranges
of IQ scores. According to the DSM-IV-TR criteria, severity levels of ID are divided as follows:
Mild (IQ level 50-55 to 70-75); Moderate (IQ level 35-40 to 50-55); Severe (IQ level 20-25 to
35-40); Profound (IQ level below 20 or 25); and Severity Unspecified (strong presumption of ID
but the individual cannot be successfully tested by standardized intelligence tests).
The Mild group comprises about 85% of those classified as ID (APA, 2000). These
individuals are often not physically distinguishable from those without ID. During infancy and
early childhood, those with mild ID may have minimal impairment in social, communication

4

skills and sensorimotor functioning. By their late teens, learning difficulties may emerge in their
academic work. During adulthood, these individuals typically live successfully in the community
with minimal assistance, although some guidance may be necessary during stressful situations
such as economic hardships (Harris, 1995).
The Moderate group comprises approximately 10% of those classified as ID (APA,
2000). Language development, social interactions, and communication skills vary across this
group. Some have the capacity to have simple conversations while others have limited
communication of basic needs (APA, 2000). These individuals also have limitations in their
achievement of self-care and motor skills into adulthood. These individuals typically need
supportive employment programs, supported workshops, and live in community-based group
homes (Harris, 1995).
The Severe group comprises approximately 3% to 4% of the ID population (APA, 2000).
These individuals typically have marked motor impairment and other associated deficits in
language, communication, and self-care. These individuals typically need supervision in task
performance in group homes or community programs (Harris, 1995).
The Profound group comprises approximately 1% to 2% of the ID population (APA,
2000). These individuals typically have neurological and physical disabilities that impair
sensorimotor functioning and language comprehension. They may have limited understanding of
simple verbal instructions and often require continual assistance with self-care. These individuals
usually benefit from highly structured environments, such as developmental centers (Harris,
1995).
Lastly, the Severity Unspecified category is reserved for cases where there is a
presumption of ID, but IQ values are unobtainable because the individual cannot be assessed by
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standard tests. This may occur when children, adolescents, and adults are uncooperative or too
impaired to participate in standardized testing (APA, 2000). These individuals typically have
physical and sensory disabilities, such as blindness, deafness, and/or severe behavioral deficits
(Harris, 1995).
Etiology of Intellectual Disability
The etiology of ID is based either on identifying a causative agent or a specific
mechanism usually diagnosed in infancy or childhood (Harris, 1995). For example, many
chromosomal abnormalities, including fragile X syndrome and Down’s syndrome can be
definitively diagnosed during pregnancy by chromosome analysis (Dykens, Hodapp, &
Finucane, 2000). Developmental errors or teratogenic factors during prenatal, perinatal, and
postnatal periods may increase the likelihood of developing ID (Alexander, 1998).
Developmental abnormalities during prenatal periods include chromosomal disorders,
syndrome disorders, inborn errors of metabolism, and developmental disorders of brain
formation. Elevated levels of alpha-fetoprotein for example, may increase the risk for neural tube
defects and trisomy chromosomal aberrations during gestation (Crocker, 1992). In approximately
20% to 30% of those with severe ID, the cause has been attributed to prenatal factors (Dykens,
Hodapp, & Finucane, 2000).
Developmental problems during perinatal periods may include intrauterine disorders and
neonatal disorders. Perinatal factors such as hypoxia, hydrocephalus, and neonatal seizures
account for approximately 11% of those with severe ID (Bernes & Kaplan, 1994). Lastly,
postnatal causes typically include head injuries, infections, degenerative disorders, seizure
disorders, toxic metabolic disorders, malnutrition, and environmental deprivation (Harris, 1995).
Exposure to environmental toxins, such as lead and mercury, account for approximately 3% to

6

12% of those with severe ID (Dykens, Hodapp, & Finucane, 2000). Conversely, it has been
estimated that between 45% and 63% of mild ID cases are attributed to unknown causes, and
very few postnatal causes have been associated with mild ID (McLaren & Bryson, 1987).
Prevalence of Intellectual Disability
Over the past 100 years the prevalence of ID has been affected by changes in diagnostic
criteria, empirical sampling, and improvements in medical care and technology (Sheerenberger,
1983). Based on empirical sampling, Baroff (1991) has suggested that only 0.9% of the
population can be assumed to have ID. Following a review of epidemiological studies, McLaren
and Bryson (1987) reported that the prevalence of ID was around 1.25% of the total population.

7

SEIZURES AND EPILEPSY
Classification and Diagnosis
Though there have always been people with seizures and epilepsy, the modern medical
era of epileptology began during the late 19th century. A British neurologist, John Hughlings
Jackson, defined seizures as an “occasioning, excessive and disorderly discharge of nerve tissue
on muscles” and recognized their effect on consciousness, sensation, and behavior (Jackson,
1890, p. 703). Prior to 1929, diagnostic measures of seizure activity and epilepsy lacked
reliability and validity, and relied heavily on direct observation. However, in 1929 technological
advances allowed for concurrent electroencephalogy and filming of patient behavior. More
recently, simultaneous EEG telemetry and video of concurrent behavior has refined our
knowledge of the relationship between epileptiform abnormalities and observed behavior
(Gastaut, 1970; Sundaram, Sadler, Young, & Pillay, 1999). Technology has greatly advanced the
ability of medical professionals to identify and differentially diagnose neurological deficits;
EEGs are now considered the gold standard among criteria for diagnosing epilepsy (Cuthill &
Espie, 2005).
The most widely accepted classification system of seizure types and epileptic syndromes
that is currently used is the International Classification of Epilepsies and Epileptic Syndromes
(ICES). This classification system, proposed by the Commission on Classification and
Terminology of the International League Against Epilepsy (ILEA) in 1989, defines an ictus (i.e.,
seizure) as a sudden neurological occurrence. Epilepsy is defined as a chronic neurological
condition characterized by recurrent epileptic seizures (Gastaut, 1973). Epilepsy is differentiated
from incidental seizures in that epilepsy is a chronic, long-lasting condition of at least two or
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more seizures and predisposes individuals to have more seizures (Adams, Victor, & Ropper,
1997).
Epileptic seizures can be classified according to their etiology, clinical manifestation, and
anatomic focus or source of origin. Epilepsy syndromes are defined by a cluster of features that
include, but are not limited to, seizure type, age of onset, heredity of seizures, EEG findings,
comorbid conditions, response to treatment, and prognosis for seizure control and remission
(Coulter, 1993). In medical literature, seizures are typically classified into two types: generalized
and partial (Wyllie, 1993).
Generalized Seizures
Generalized seizures usually have a unilateral focus that spreads to become generalized.
These seizures are accompanied by a widespread electrical discharge involving both
hemispheres. They are typically divided into tonic-clonic seizures, absence seizures, and other
generalized seizures. Generalized tonic-clonic seizures are the most common epileptic
manifestation of childhood neurological diseases (Holmes, 1997). These seizures typically
involve somatosensory auras that may include visual, auditory, olfactory, and gustatory
experiences prior to the onset of a seizure (Tuxhorn, 2005). During a tonic-clonic seizure,
stiffening of extremities (tonic phase), rhythmic jerking of an extremity or the whole body
(clonic phase), and loss of consciousness occur (Trimble, Ring, & Schmitz, 2000).
The second type of generalized seizures, absence seizures, are subtler than tonic-clonic
seizures because they occur suddenly and are often mistaken for daydreaming. These individuals
may appear to have a blank facial expression, suffer from loss of consciousness, and may have
automatisms in the form of lip smacking, licking, chewing, and finger movements (Tuxhorn,
2005). Subtypes of absence seizures include typical and atypical. Typical absence seizures are
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often very brief and involve loss of consciousness only. In contrast, atypical absence seizures last
longer and may involve tonic, clonic, or automatic movements (Holmes, 1997). Although
atypical absence seizures are characteristically similar to absence seizures, they are often
associated with other types of seizures and are typically more difficult to control with
antiepileptic medications (Schiff, Labar, & Victor, 1999).
Other generalized seizures include tonic, clonic, myoclonic, and atonic seizures. These
seizures represent the least common types of generalized seizures (Adams, Victor, & Ropper,
1997). Unlike tonic-clonic seizures, tonic and clonic seizures occur independently but have
tonic-clonic features such as loss of consciousness (Trimble, Ring, & Schmitz, 2000). Myoclonic
and atonic seizures are differentiated from tonic and clonic seizures because loss of
consciousness does not occur during these episodes (Mangano, Fontana, & Cusumano, 2005).
Myoclonic seizures are characterized by single or repetitive contractions of a muscle or group of
muscles, whereas atonic seizures are characterized by sudden, momentary loss of posture or
muscle tone. Generalized myoclonic, atonic, and tonic seizures are all features of the LennoxGastaut syndrome common in the ID population. The Lennox-Gastaut syndrome is defined as the
presence of slow-spike wave complexes in individuals with tonic seizures and more than one
other seizure type (Aicardi & Gomes, 1988).
Partial Seizures
Unlike generalized seizures, partial seizures begin in a specific area of one cerebral
hemisphere and do not spread bilaterally (Holmes, 1997). Partial seizures, which are associated
with lesions of the temporal lobe (Schiff, Labar, & Victor, 1999), are subdivided into simple
partial seizures (in which consciousness retained); and complex partial seizures (in which
consciousness is impaired or lost) (Kotagal, Rothner, Erenberg, Cruse, & Wyllie, 1987). Both

10

simple and complex partial seizures are often accompanied by somatosensory auras, including
complex visual or auditory hallucinations (Janszky, Schulz, & Ebner, 2004). Additionally, partial
seizures may spread to cause a generalized seizure, in which case the classification category is
partial seizures secondary generalized (Holmes, 1997).
Etiology of Epilepsy
According to the ICES (1989), there are three etiological classifications of epilepsy.
These etiological classifications include confirmed, suspected, and unknown. Potential factors
leading to the presence of epilepsy include a genetic predisposition, alternations in neuronal and
neurotransmitter metabolism, electrophysiological abnormalities, and neuropathic changes
(Adams, Victor, & Ropper, 1997). Additionally, there are certain etiological factors associated
with age of onset. More specifically, in infancy and early childhood, chromosomal abnormalities,
congenital disorders, metabolic disorders, and brain infections (e.g., encephalitis, meningitis), are
considered to be the most common etiological factor (Okumura et al., 2000). In young adults,
head trauma and brain tumors are the most common cause of seizures. In older adults, comorbid
physical and neurological conditions (e.g., cerebrovascular disease, degenerative disease) are the
most common cause (Gareri, Gravina, Ferreri, & De Sarro, 1999). Although numerous causes of
epilepsy are known, it has been estimated that underlying causes of epilepsy is unknown in up to
50% of cases (Wyllie, 1993).
Prevalence of Epilepsy
Given the complex nature of classifying and diagnosing seizures and epilepsy, it is not
surprising that prevalence rates vary. Possible explanations for this phenomenon include newly
diagnosed cases of unprovoked seizures, the utilization of various diagnostic criteria in
experimental settings, and lack of standardized definitions of seizure control (Mohanraj &
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Brodie, 2005). Nevertheless, Hauser and Hesdorffer (1990) estimate that epilepsy affects
approximately 1% to 3% of the general population. Further, these researchers suggest that
approximately 1% of persons within the United States will have epilepsy by the age of 20.
Prognosis
Treatment outcome depends on the etiology of the epilepsy, the frequency, intensity,
duration, and type of seizures. Seizures with particularly bad prognostic features include epilepsy
associated with congenital neurological deficits, progressive neurological disorder, suspected or
unknown etiology, partial epilepsies, and those with Lennox-Gastaut syndrome (Berg et al.,
2001; Drislane & Schomer, 1994; Rantakallio, von Wendt, & Koivu, 1987). All of these
conditions have particularly high associations with ID (Chevrie & Aicardi, 1978; Lennox, 1960;
Koo & Holmes, 1999; Okumura, 2000; Yamanouchi et al., 2005).
Treatments
There are two types of treatments available for epilepsy: pharmacological and surgical.
The first line of epilepsy treatment is pharmacological. This typically includes an AED regimen
and therapeutic drug monitoring via laboratory testing of blood levels (Patil & Bodhankar, 2005;
Specht, Elsner, May, Schimichowski, & Thorbecke, 2003). However, those who do not achieve
satisfactory seizure control despite adherence to pharmacological interventions (i.e., refractory
epilepsy) are often considered candidates for specific surgical interventions. Characteristics of
good candidates for brain surgery include those with a distinct epileptic focus in a surgically
removable area of the brain (e.g., lobectomy, hemispherectomy). Individuals with additive
handicaps such as ID or multi-epileptic foci are often considered to be poor candidates for brain
surgery (Wilfong, 2002). However, in individuals with refractory epilepsy and where removal of
brain tissue is not feasible, these individuals are sometimes considered for vagal nerve
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stimulation (VNS) surgery (Andriola & Vitale, 2001). The vagal nerve stimulator is an electrode
that is surgically implanted around the left vagus nerve and normalizes electrical pulses to the
brain (Gates, Huf, & Frost, 2001). The normalization of neuronal activity mitigates the frequency
and severity of seizures in some individuals (Huf, Mamelak, & Kneedy-Cayem, 2005).
Pharmacological Treatment
Antiepileptic drugs are traditionally used in the treatment of epilepsy. There are two
families of AEDs: classic and newer. Classic AEDs include phenobarbital, phenytoin, primidone,
ethnosuximide, carbamazepine, benzodiazepines, and valproate (Herranz, Armijo, & Arteaga,
1988). Newer AEDs, which include oxcarbazepine, gabapentin, lamotrigine, and sabril,
reportedly have less toxicity than classic AEDs with respect to the central nervous system (CNS;
Harden, 1997).
Based on their psychotropic properties and mechanisms of action, classic and newer
AEDs are generally classified as sedating or activating (McDonnell & Morrow, 1996). Sedating
AEDs (e.g., barbiturates, benzodiazepines, valproic acid, gabapentin, tiagabine, and vigabatrin)
are associated with fatigue, cognitive slowing, and possible anxiolytic and antimanic effects.
These actions may be related to a predominance of potentiation of y-adminobutyric acid
(GABA) inhibitory neurotransmission (Ketter, Post, & Theodore, 1999). Activating AEDs (e.g.,
felbamate and lamotrigine) have possible anxiogenic and antidepressant effects, such as
agitation, aggression, irritability, and hyperactivity, and are associated with attenuation of
glutamate excitatory neurotransmission (Reijs, Aldenkamp, & De Krom, 2004).
Although significant pharmacological advances have been made in the treatment of
epilepsy, it is evident that none of the major AEDs are free from untoward side effects (SE;
Brodie, 2001). There are generally five domains of SE individuals experience from AED use.
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These domains include cognition, mood, behavior, motor, and physical effects (Gates, 2000;
Glauser, 2004; Reijs, Aldenkamp & Krom, 2004). The most common SE of cognitive
impairments includes decreased performance on intelligence tests, memory, attention, confusion,
and processing speed (Drane & Meador, 2002). Side effects associated with both classic and
newer AEDs include dizziness, abnormal vision, ataxia, tremors, hepatic toxicity, nausea,
vomiting, gastrointestinal problems, alopecia, rash, and weight changes (Buchanan, 1992;
Carpay, Aldenkamp, & van Donselaar, 2005).
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INTELLECTUAL DISABILITY AND EPILEPSY
Classification and Diagnosis
Similar to the diagnosis of epilepsy in the general population, a diagnosis of epilepsy in
individuals with ID is based on patient history information (Richardsson, Koller, & Katz, 1981).
Oftentimes the causative agent of ID is considered when diagnosing epilepsy in this population,
as they often have a common etiology (Coulter, 1993). For example, prevalence studies indicate
that 5% to 50% of individuals with mild and moderate ID have epilepsy and 30% to 70% with
severe and profound ID have epilepsy (Coulter, 1993; Marcus, 1993; Pellock & Hunt, 1996). It is
well established that there is a significant positive correlation between the incidence of epilepsy
and severity of ID (Heller, 1969; Ieshima & Takeshita, 1988; Kumada et al., 2005; Marcus,
1993). For example, in a study of 1479 children and adults, Forsgren and colleagues (1990)
found that 299 patients had comorbid ID and epilepsy. Of the 299 patients with ID and epilepsy,
14% had mild ID, 20.4% had moderate ID, 34.8% had severe ID, and 30.8% had profound ID.
However, an important consideration is that reported rates differ between researchers.
Prevalence of Intellectual Disability and Epilepsy
Prevalence rates of epilepsy are much higher in children and adults with ID than in the
general population (Corbett, Harris, & Robinson, 1975; Forsgren, Edvinsson, Blomquist,
Heijbel, & Sidenvall, 1990; Ieshima & Takeshita, 1988; Kumada et al., 2005; McDermott,
Moran, & Platt, 2005; Pary, 1993). Currently, the cumulative risk of epilepsy increases
substantially in persons with ID if there are any co-morbid conditions such as cerebral palsy,
movement disorders, cerebral injury, and degenerative CNS diseases (Amano et al., 2000; Cole,
2002; Goulden, Shinnar, Koller, Katz, & Richardson, 1991; Mariani, Gerini-Strambi, Sala,
Erminio, & Smirne, 1993). Other risk factors for epilepsy in older-onset cases include
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individuals with Down’s syndrome, those with vascular disease, brain tumors, Alzheimer’s
syndrome, and multiple sclerosis (Wyllie, 1993).
In fact, rates of epilepsy have been estimated to be approximately 40% to 60% in
institutionalized ID populations (Mattson, 1996). This increased rate is due to the fact that many
individuals with ID have comorbid neurological disorders, as well as epilepsy. For example,
approximately three to six children per 1000 births are afflicted with cerebral palsy, moderate or
severe ID, or both (Steffenburg, Hagberg, &Kyllerman, 1996). Moreover, it has been estimated
that one third of those with ID and cerebral palsy have epilepsy (Richardsson, Koller, & Katz,
1981).
Pharmacological Treatment
In the past decade there has been an emphasis on polypharmacy reduction and a shift
from using classic AEDs to newer AEDs in the ID population (Bourgeois, 2001; Bennet,
Dunlop, & Ziring, 1983; Ettinger, Barr, & Solomon, 2001; Kelly, Stephen, & Brodie, 2004;
Mattson, 1996; Pellock & Hunt, 1996; Poindexter, Berglund, & Kolstoe, 1993). Research has
shown that newer AEDs are better tolerated in those with ID and multiple handicaps (Pellock,
2002; Perucca, Beghi, Dulac, Shorvon, & Tomson, 2000). Despite this, polytherapy and classic
AED use are still common practice in institutionalized ID populations because withdrawal of
these drugs after long-term exposure may cause an increase in seizures (Genton, 2000;
Goeckner, Rosenfeld, & Weber, 1995) or unmanageable behavior (Baumeister & Sevin, 1990;
Clarke, Kelley, Thinn, & Corbett, 1990; Kerr, 2002; Matson et al., 2000), even when appropriate
AEDs are prescribed and blood levels are in their therapeutic ranges (Patil & Bodhankar, 2005;
Specht, Elsner, May, Schimichowski, & Thorbecke, 2003). For example, Pellock and Hunt
(1996) conducted an open 10-year study with 244 individuals with ID and epilepsy. These
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researchers found that in this sample the most frequently administered AEDs were phenobarbital
(69%), phenytoin (21%), primidone (8%), and carbamazepine (1%). Similar patterns of AED use
have been documented in other studies (Matson, Mayville, & Bamburg, 2001; Mattson, 1996;
Pellock, 2002).
Barbiturates
Barbiturates are generalized CNS depressants and have historically been regarded as the
first choice in treating recurrent seizures (Porter & Melldrum, 1990). Common barbiturates
include phenobarbital and primidone and are used to treat generalized tonic-clonic seizures and
partial seizures (Vinning, Carpenter, & Aman, 1999; Pellock, 2002). Phenobarbital and
primidone modulates GABA at the postsynaptic receptor (Porter & Meldrum, 1990). Common
SE of phenobarbital and primidone include sedation, rash, ataxia, and disturbances of cognition,
mood, and behavior (Rogvi-Hansen & Gram, 1995; DeToledo, Lowe, & Haddad, 2002; Pellock
& Hunt, 1996). Phenobarbital also induces hepatic microsomal metabolism; thus, the likelihood
for drug interactions is extremely high when it is used as co-therapy (Patsalos & Perucca, 2003).
One of the most commonly reported SE in the general population is drowsiness (Harbord, 2000).
Although barbiturates have sedating effects, hyperactivity and irritability are frequently observed
in those with ID (Glauser, 2004; Goeckner, Rosenfeld, & Weber, 1995; Pellock, 2002). Given
the severity of these SE in the ID population, barbiturates are becoming less frequently used and
are generally reserved for those with refractory epilepsy (Pellock, 2002).
Phenytoin
Historically, phenytoin has been a first-line medication for the prevention of tonic-clonic
seizures, partial seizures, and acute seizure management (i.e., status epilepticus) (Pellock, 2002).
Phenytoin blocks sustained high-frequency repetitive firing of action potentials by altering
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sodium, potassium, and calcium conduction of membrane potentials (Porter & Meldrum, 1990).
Unlike phenobarbital, phenytoin is one of the best-tolerated AEDs in the general population and
does not have sedative effects (Porter & Meldrum, 1990). In the ID population however, serious
neurological damage has been associated with phenytoin, such as deterioration of cognitive
functioning and ataxia (Iivanainen, 1998). In addition, Matson et al., (2004) found that phenytoin
use was associated with significant deficits in social skills in the ID population. Less serious SE
of phenytoin includes cosmetic SE, such as gingival hyperplasia and hirsutism, which are more
prevalent after chronic administration, higher doses, and polypharmacy (Buchanan, 1992;
Pellock, 2002).
Carbamazepine
Carbamazepine has gained acceptance as a first-line treatment for tonic-clonic seizures,
partial seizures (Waisburg & Alvarez, 1998), and secondary generalized seizures in those with
ID, as well as comorbid psychiatric disease (Kanner, 2002; Pellock, 2002). The mechanism of
action is similar to phenytoin, it acts pre-synaptically to decrease synaptic transmission but does
not influence GABA uptake (Porter & Meldrum, 1990). Side effects of carbamazepine are
similar to that of phenytoin (Herranz, Armijo, & Arteaga, 1988), including drowsiness,
irritability, nausea and vomiting, nystagmus, and hepatic failure (Gates, 2000). However, due to
its minimal SE on cognition and behavior, carbamazepine is widely used in persons with ID
(Alvarez, Besag, & Iivanainen, 1998; Matson, Luke, & Mayville, 2004).
Valproate
Valproate, in the form of valproic acid or salt, is a broad-spectrum AED. It reduces the
incidence and severity of tonic–clonic, absence, myoclonic, and partial seizures. It is frequently
used in the ID population because those with one or more seizure type are often responsive to
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valproate and suffer from relatively few SE with respect to cognition and behavior (Friis, 1998).
Like phenytoin and carbamazepine, valproate blocks high-frequency repetitive firing of neurons
at therapeutically relevant concentrations (Porter & Meldrum, 1990). Common SE include
weight gain, tremor, hyperactivity, drowsiness, alopecia, and gastrointestinal upset (Buchanan,
1992; Gates, 2000). Although valproate may have moderate SE in some individuals, it continues
to be administered in the ID population because of its efficacy against refractory epilepsy and its
utility in mitigating comorbid behavioral aberrations such as impulsive-aggressive behavior
(Gates, 2000; Pellock, 2002; Rutecki & Gidal, 2002).
Benzodiazepines
Benzodiazepines are used primarily for status epilepticus and refractory epilepsy, which
are common in the ID population (Lombroso, 1983; Pellock, 2002). There are six
benzodiazepines that include clonazepam, lorazepam, and diazepam, clorazepate, midazolam,
nitrazepam, and clobazam. Clonazepam and clorazepate are used for chronic treatment, whereas
diazepam is used in the treatment of status epilepticus. Clonazepam is also used for absence,
myoclonic, and atonic seizures where control with other drugs is difficult (Vinning, Carpenter, &
Aman, 1990). All benzodiazepines have sedative properties that include drowsiness, somnolence,
and fatigue (Gates, 2000). Benzodiazepines are generally not preferred because of the relatively
high frequency of SE on cognition, mood, and behavior (Wyllie, 1993).
Lamotrigine
Lamotrigine has been indicated for treatment of generalized tonic-clonic seizures and
partial seizures. Lamotrigine inhibits glutamate and aspartate release, blocks sodium channels,
and prevents repetitive firing or neurons. It is chemically unrelated to other AEDs and is
therefore commonly used as adjunctive therapy in adults. However, individuals with ID treated
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with lamotrigine are at risk of experiencing Sturge-Johnson syndrome, a severe rash that can be
irritating or fatal when combined with valproate (McKee et al., 2003). Other less severe SE from
lamotrigine includes dizziness, headache, ataxia, somnolence, and hematologic abnormalities
(Kustra et al., 2005).
Assessment of Antiepileptic Side Effects
Susceptibility to SE is inherent in all medications, especially in populations that
experience long-term use (Clarke, Kelley, Thinn, & Corbett, 1990; Stein & Strickland, 1998). It
has been estimated that approximately 25% to 30% of those with epilepsy in the general
population will experience a recurrence of seizures despite appropriately prescribed medications
and blood levels in therapeutic ranges (Patil & Bodhankar, 2005; Specht, Elsner, May,
Schimichowski, & Thorbecke, 2003). This recurrence rate is even greater (i.e., 40%) in those
with multiple handicaps, including ID (Singh & Towle, 1993). As a result, individuals with ID,
especially those in institutionalized environments often experience long-term AED use because
withdrawal from these drugs has been shown to increase seizures (Alvarez, Besag, Iivanainen,
1998; Pellock & Morton, 2000).
Despite the long history of AED availability and research on their efficacy, individual
differences in clinical response and inconsistent research methodologies confound efforts to
achieve a broad consensus regarding their psychoactive effects (Brodie, 2001; Chadwick, 1997;
Harbord, 2000; McDonnell & Morrow, 1996; Meldrum, 2002; Mohanraj & Brodie, 2005;
Perucca, 2002; Stein & Strickland, 1998). Selecting a specific AED for seizure treatment in those
with ID requires a balance of the drug’s likely efficacy for both seizures and comorbid disorders
and minimizing SE (Perucca et al., 2000). In both the general and ID population, SE may be
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tolerated or heightened, producing toxicity that may require dosage reductions (Alvarez, Besag,
& Iivanainen, 1998; Matson, Mayville, & Bamburg, 2001; McKee, et al., 2003).
Assessing SE of AEDs in the ID population, however, poses considerable challenges not
experienced in the general population (Alvarez, 1989). For example, information used to assess
SE of AEDs in individuals with epilepsy is typically gathered by self-report, interviews, and
direct observations (Mayville & Matson, 2004). However, individuals with ID and epilepsy
generally have significant cognitive deficits and are frequently non-verbal, thus making selfreport measures or interviews with the patient ratings inappropriate. These factors contribute to
the complexity of assessment, treatment, and monitoring of SE in this population (Matson,
Bielecki, Mayville, & Matson, 2003).
Given the limitations of patient self-report with this population, informant-based ratings
scales, direct observations, and laboratory monitoring have become the primary method of
assessing seizure activity and SE in these individuals (Mayville & Matson, 2004). Although
some standardized measures on SE of AEDs in the general population exist (Kane, Lee, BryantComstock, & Gilliam, 1996), research on SE of AEDs in institutionalized ID population is sparse
and lacks systematic, reliable, and valid measures (Matson et al., 2000; Mayville & Matson,
2004). However, a recent study assessing the reliability of the SEIZES-B, designed to measure
SE specific to AED use in the adult ID population, indicated moderately high overall inter-rater
reliability (r = .72) and moderately high overall test-retest reliability (r = .63) (Matson, Laud,
González, Malone, & Swender, 2005). The SEIZES-B scale addresses observable SE, as
opposed to other scales that estimate subjective ratings of SE such as quality of life. The current
study aims to further examine the psychometric properties of the SEIZES-B.
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STUDY ONE
Rationale
Presently, there is a lack of research on standardized measures assessing SE of AEDs in
individuals with ID and epilepsy. To date, no research has been conducted on the convergent
validity of two measures assessing SE of AEDs in this population. Since this population is
medically fragile, standardized measures assessing SE of AEDs are needed. Effectively
monitoring SE of AEDs may allow medical professionals to adjust dosages, especially when
multiple medications are in use. The purpose of this study was to further investigate the
psychometric properties of the SEIZES-B. The current study’s purpose had two goals. First,
interrater reliability of direct observations using the Pinecrest Developmental Center (PDC)
Nursing Assessment Form was explored. A licensed epileptologist and registered nurse served as
the observers. Second, as direct observations and third-party report are the gold standards
available for this population (Cramer & Mattson, 1993; Mayville & Matson, 2004), the
epileptologist’s direct observation ratings from the PDC Nursing Assessment Form was the
standard against which the SEIZES-B was compared. This comparison served as a measure of
convergent validity.
Method
Participants
Participants were resident patients of PDC in central Louisiana. PDC is a state-run
residential community that provides 24-hour care to approximately 550 individuals with varying
levels of ID, ages, genders, and races. An on-site licensed psychologist or board certified
psychiatrist diagnosed all participants with ID based on DSM-IV-TR criteria (e.g., deficits in
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intellectual and adaptive functioning before 18 years of age). Approval from the PDC
Institutional Review Board (IRB) was obtained prior to data collection.
A power analysis was conducted to determine the sample size of the group required for
the present study. The recommended level of power was set at .80, because alpha (α) or the
predetermined level of significance was set at .05 (Cohen, 1988). Using GPOWER (Faul, &
Erdfelder, 1992), a statistical program for determining power levels, it was determined that a
total sample of 82 participants would be required to obtain significance for variance-based
statistics at the .05 level.
Seventy nine individuals with varying levels of ID were recruited for inclusion in this
study. During the course of data collection, six participants were removed from data analysis due
to missing Nursing Assessment Form ratings from the epileptologist, leaving 73 participants.
Participants included 43 males and 30 females diagnosed with mild (n = 1), moderate (n = 1),
severe (n = 11), profound (n = 59), and unspecified (n = 1) ID. Of these participants, the majority
were Caucasian (n = 51), with a smaller sub-sample of African Americans (n = 21), and a small
sample identified as other (n = 1). Participants’ ages ranged from 25 to 89 years, with an average
age of 49 years. Demographic information is presented in Table 1.
Diagnosis of epilepsy was made by a consulting licensed neurologist who reviewed
patient medical histories prior to data collection. Classification of seizure type, determined by the
neurologist, was based on the ILEA criteria, clinical description of seizure activity, EEG pattern,
and additional medical information (e.g., family history, age of onset, prior neurological trauma).
Individuals who were excluded from participating in this study were those with: 1) non-epileptic
seizures and, 2) no seizure activity for the past two years.
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Table 1
Demographic Characteristics of Participants
______________________________________________________________________________
Characteristic
n
%
______________________________________________________________________________
Age at time of survey (years)
0-21

1

1.4

22-45

32

44.5

46-65

31

43.1

66+

9

12.3

Female

43

58.9

Male

30

41.1

Caucasian

51

69.9

African American

21

28.8

Other

1

1.4

Mild

1

1.4

Moderate

1

1.4

Severe

11

15.1

Profound

59

80.8

Gender

Race

Level of Mental Retardation

Unspecified
1
1.4
______________________________________________________________________________
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Of the 73 participants with ID and epilepsy, five seizure types were noted in the sample.
The majority of the participants had partial epilepsy (n = 56), with 11 evolving into generalized
seizures (i.e., partial seizures secondary generalized). Other seizure types included generalized (n
= 6), Lennox-Gastaut (n = 7), and epilepsy NOS (n = 4). These diagnoses were noted during the
chart review and are listed in Table 2.
Table 2
Classification of Seizure Types
______________________________________________________________________________
Classification
n
%
______________________________________________________________________________
Generalized

6

8.2

Partial

45

61.6

Partial seizures secondary generalized

11

15.1

Lennox-Gastaut

7

9.6

Epilepsy NOS
4
5.5
______________________________________________________________________________
Since dosage and regimen of medications may have an impact on the presence and
severity of SE, current medication use was noted during the participants’ chart review. All
participants were on at least one AED at the time of review. Twenty seven participants (37%)
were on one AED, 29 participants (39.7%) were on two AEDs, 16 participants (21.9%) were on
three AEDs, and one participant (1.4%) was on four AEDs. Overall, the use of classic AEDs
(95.9%) versus newer AEDs (82.19%) did not differ substantially. See Table 3.
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Table 3
Medication Usage
______________________________________________________________________________
Frequency Count
n
%
______________________________________________________________________________
Classic AEDs
Carbamazepine

17

23.2

Clonazepam

3

4.1

Diastat

21

28.8

Diazepam

2

2.7

Lorazepam

1

1.4

Phenobarbital

1

1.4

Phenytoin

7

9.6

Primidone

2

2.7

Valproic Acid

16

21.91

Gabapentin

1

1.4

Lamotrigine

24

32.9

Levetiracetam

10

13.7

Oxcarbazepine

5

6.9

Pregabalin

13

17.8

Topiramate

2

2.7

Newer AEDs

Zonisamide
5
6.9
______________________________________________________________________________
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Measures
The Scale for the Evaluation and Identification of Seizures, Epilepsy, and
Anticonvulsant Side Effects B (SEIZES-B). The SEIZES-B is a 52-item informant based
instrument designed to measure SE specific to AED use in adults with ID and epilepsy.
According to symptom severity, the informant rates items on a four-point Likert-type scale. The
scale addresses the following topics which map onto 14 subscales that cover features of adverse
SE from AED use: 1) Hematological Disturbances, 2) Electrolyte Disturbances, 3) Hepatic
Disturbances, 4) Weight Disturbances, 5) Respiratory Disturbances, 6) Gastric Disturbances, 7)
Dermatological Changes, 8) Hair Changes, 9) Gait Disturbance, 10) Tremor, 11) Sedation, 12)
Affective disturbances (e.g., depression, tension/agitation anger/hostility), 13) Cognitive
disturbances (e.g., decreased concentration and attention), and 14) Drug-related Dizziness (e.g.,
gait/movement disturbances).
Symptom severity is rated as follows: a score of ‘0’ indicates no disturbance; a score of
‘1’ indicates mild problems; a score of ‘2’ indicates moderate problems; whereas a score of ‘3’
indicates impairment in everyday functioning. Only one item from each subscale may be
endorsed since items are rated on a continuum of increasing severity, with the exception of the
following four subscales; 1) Gastric Disturbances, 2) Dermatological Disturbances, 3) Hair
Changes, and 4) Sedation. These four subscales may have more than one item endorsed since
multiple symptoms may be experienced. For example, in the gastric subscale, endorsement of
item 19a, “Vomiting shortly after medication is given” may be experienced concurrently with
endorsement of item 19b, “Vomiting throughout the day”. The endorsement of item 19a would
yield a score of ‘2’ and endorsement of item 19b would yield a score of ‘3’. Therefore, the total
item score for the gastric subscale would equal ‘5’.
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The total score for each endorsed item is recorded in the corresponding numbered item
space on Section B of the SEIZES-B scoring sheet. The number representing the total item score
for each subscale is then circled on the scoring scale located above the individual item
endorsement section and yield s a SEIZES-B profile.
Direct Observation Method. Direct observations of behavior were completed
using the PDC Nursing Assessment Form. The PDC Nursing Assessment Form covers 15
physiological and psychosocial domains designed to closely monitor each patient. The PDC
epileptologist and neurologists do not typically complete the Nursing Assessment Form. A
registered nurse, with a background in neurology and psychopharmacology, completes the form
after each neurology clinic visit. The assessment takes approximately 10 minutes to complete.
The 15 domains include: 1) Vital Signs, 2) Level of Consciousness/Cognition, 3) Reaction to
Stimulus (e.g., change in response to stimuli, extremity movement, general withdrawal, tremor),
4) Psychosocial (e.g., cooperation, restless/anxious, irritable, hostile/uncooperative), 5) Eyes,
Nose, Throat, Sleep Patterns, Rest Patterns, 6) Cardiovascular (e.g., apical pulse, radial pulse,
pedal pulse), 7) Respiratory (e.g., breath sounds, character of respirations, muscular
contractions/reactions, cough sputum), 8) Gastrointestinal (e.g., bowel sounds, abdomen), 9)
Bowel (e.g., stools, color of stools), 10) Renal Appearance, 11) Musculoskeletal (e.g.,
locomotion, balance, edema), 12) Skin (e.g., color, temperature, turgor, condition), 13) Dental
(e.g., oral hygiene rating), 14) Reproductive System (e.g., masses, dimpling, discharge), and 15)
Seizures (e.g., activity, acute episode, post-ictal state, VNS, any changes in seizure type,
frequency, and duration). Spaces are provided next to each domain to record an absence or
presence of symptoms. A blank box indicates an absence of symptoms whereas a checkmark in
the box indicates the presence of symptoms.
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Procedure
Participants were seen at the PDC neurology clinic each week for a period of two months.
Prior to each visit, the nurse and epileptologist were given the PDC Nursing Assessment Forms.
These forms were attached to the participant’s medical chart. The nurse and epileptologist were
instructed to directly observe the participant and complete the form independently for those that
attended clinic. After the forms were completed, a list of participants that attended clinic that
week was complied. The SEIZES-B was then administered for those participants who came into
clinic that week. This control measure was taken in order to avoid time-order confounding
effects.
Administration of the SEIZES-B was conducted by a bachelors-level clinical psychology
graduate student. The graduate student served as the interviewer. The interviewer was trained
specifically in the administration and scoring of the SEIZES-B before data collection began.
Interviews took place in a quiet area of the participants’ homes and took approximately 10
minutes to complete. Direct-care staff members who had known the participant for at least six
months prior to the study served as informants. Each item was read to the direct-care staff
members verbatim. Upon completion of the item, the interviewer instructed the direct-care staff
to provide a rating. Information from the first four subscales of the SEIZES-B was collected
from the participants’ medical records by the interviewer. However, this information was not
included in the analysis.
In order to estimate convergent validity, eight subscales of the SEIZES-B were compared
to the corresponding items of the PDC Nursing Assessment Form. Subscales from the SEIZES-B
that corresponded with the domains from the Nursing Assessment Form included: 1) Respiratory
Disturbances, 2) Gastric Disturbances, 3) Dermatological Disturbances, 4) Gait Disturbances, 5)
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Tremor, 6) Sedation, 7) Affective Disturbances, and 8) Cognitive Disturbances. Items from the
PDC Nursing Assessment Form that did not overlap or could not be observed during the clinic
visit with the SEIZES-B were not utilized in the comparisons (e.g., Hair Changes, Drug Related
Dizziness, Sleep and Rest Patterns).
Results
Interrater Reliability of the Direct Observation
Interrater reliability of the direct observation using the PDC Nursing Assessment Form
was calculated using Cohen’s kappa correlation coefficient (κ) in order to measure agreement
between dichotomous variables (presence versus absence of symptoms) while removing chance
agreement (Hinkle, Wiersma, & Jurs, 1998). This was used to assess whether the nurse and
epileptologist’s ratings were consistent between observers. Results revealed that the highest
individual item kappa correlation was κ = .53, p<.05 for Alert/Awake. However, overall, the
majority of the items reflected low positive correlations (Hinkle, Wiersma, & Jurs, 1998). For
example, 5 out of the 14 correlations fell below κ = .00. In addition, for a number of items no
statistics could be computed because the variable was a constant (e.g., shallow breathing, deep
breathing, emesis, rash, and excoriated skin). The individual item interrater reliability of the
direct observation is shown in Table 4.
Table 4
Interrater Reliability of the Direct Observation
______________________________________________________________________________
Domain
κ
__________________________________________________________________________________
Respiratory
Regular Respiration

-.02
(table continued)
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(table continued)
Gastrointestinal
Guarding

-.01

Normal Color Skin

-.02

Pale Color Skin

.02

Skin

Musculoskeletal
Gait Steady

.44

Change in Gait/Balance

.31

Reaction to Stimulus
Intermittent Tremor

-.06

Frequent/Constant Tremor

.25

Psychosocial
Irritable

.48

Hostile/Uncooperative

.25

Levels of Consciousness/Cognition
Alert/Awake

.53

Sedated/Drowsy

.30

Lethargic

.25

Change in Cognitive Functioning

-.01
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Convergent Validity of the SEIZES-B
Concordance between the SEIZES-B and direct observation were calculated using
Pearson-product moment correlation coefficients (Tabachnick & Fidell, 2001). The results of the
correlational analyses were not statistically significant for five of the following domains: Gastric
Disturbances, Dermatological Disturbances, Tremor, Affective Disturbances, and Cognitive
Disturbances. The correlation coefficients of the individual items ranged from -.06 for tremor, to
.97 for Gait Disturbance. However, some of the participants were non-ambulatory; therefore this
item was only calculated for a subset of the sample. Concordance between items of the SEIZESB and direct observation yielded a very high positive correlation for Gait Disturbance, r =.97,
p<.001 and low positive correlation for Sedation, r =.26, p<.05. Most of the correlation
coefficients could be classified as having low positive to little if any clinical significance
(Hinkle, Wiersma, & Jurs, 1998). No statistics were available for Respiratory Disturbance
because the variable on the PDC Nursing Assessment Form was a constant. Concordance rates
for the SEIZES-B and direct observation are presented in Table 5.
Table 5
Corresponding Total Subscale Scores of the SEIZES-B and Direct Observation
______________________________________________________________________________
SEIZES-B
Nursing Assessment Form
r
______________________________________________________________________________
Respiratory Disturbance

Respiratory

--

Gastric Disturbances

Gastrointestinal

-.02

Dermatological Disturbances

Skin

-.03

Gait Disturbances

Musculoskeletal

.97***
(table continued)
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(table continued)
Tremor

Reaction to Stimulus

-.06

Sedation

Level of Consciousness/Cognition

.26*

Affective Disturbances

Psychosocial

.21

Cognitive Disturbances
Level of Consciousness/Cognition
-.01
______________________________________________________________________________
-- unable to calculate due to lack of variance
***

p < .001

*

p < .05
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STUDY TWO
Rationale
The purpose of this study was to investigate differences in the baseline level of
symptomatology across individuals with ID. Three groups, comprised of those with epilepsy
taking AEDs, those with a diagnosis of epilepsy not taking AEDs, and those without epilepsy
taking antipsychotic medications were compared. Individuals without epilepsy taking
antipsychotic medications served as the control group to determine if significant differences in
the baseline level of such symptoms existed. Based on the available research (Alvarez, Besag, &
Iivanainen, 1998; Brodie, 2001; Ettinger, Barr, & Solomon, 2001; Gates, 2000), it was
hypothesized that those with epilepsy taking AEDs would have higher SE ratings than those not
taking AEDs and those taking antipsychotic medications because the SEIZES-B was developed
to assess SE specific to AED use. The relationship between the baseline level of SE symptoms in
those taking AEDs, non-AEDs, and anti-psychotics has not been researched in the literature.
Following the comparison across the three groups for overall SE profiles, a series of item
correlation coefficients within ten subscales of the SEIZES-B was conducted. This analysis was
exploratory and indicated whether a relationship existed between specific items of the SEIZES-B
across the designated groups.
Method
Participants
Participants were recruited from PDC in central Louisiana. Individuals participating in
this study were those with a diagnosis of ID.
A power analysis was conducted to determine the sample size of the groups required for
the present study. Using GPOWER (Faul & Erdfelder, 1992) with a predetermined level of
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significance set at .05 (Cohen, 1965; 1988), it was determined that a total sample of 159
participants was required for an ANOVA with three groups for a medium effect size (.5). The
present study only had 15 participants in each group, with a total sample size of 45. While this
small sample size serves as a limitation of this study, the study remains important given the
importance of this topic.
Three groups of individuals with ID participated in this study. They included individuals
with epilepsy taking AEDs (n = 15), individuals with a diagnosis of epilepsy not taking AEDs (n
= 15), and individuals without epilepsy taking antipsychotic medications (n = 15). Participants
were matched across groups for age (within 10 years), gender, race, level of ID, seizure type
(where appropriate), and medication type to prevent confounding effects these variables might
produce prior to data collection. Categorical variables like gender, race, level of ID, seizure type,
and number of psychotropic medications, were compared using chi-square analysis. Based on
these analyses, there were no significant differences in these variables.
Age, a continuous variable, was compared using a one-way ANOVA. Based on this
analysis, there were no significant differences in age. Participants’ ages ranged from 26 to 87
years, with the average age of 52 years. There were 34 males and 11 females with mild (n = 0),
moderate (n = 7), severe (n = 12), profound (n = 25), and unspecified (n = 1) ID. The majority of
the participants were Caucasian (n = 33) and a smaller sub-sample were African American (n =
12). Demographic information is presented in Table 6.
Diagnosis of epilepsy was made by a consulting neurologist who reviewed patient
medical histories prior to data collection. Classification of seizure type, determined by the
neurologist, was based on ILEA criteria, clinical description of seizure activity, EEG pattern, and
additional medical information. These diagnoses were noted during the chart review.
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Table 6
Demographic Characteristics of Groups
______________________________________________________________________________
Characteristic
AED (n = 15)
Non-AED (n = 15) Control (n = 15)
______________________________________________________________________________
Age
0-21

0 (0%)

0 (0%)

0 (0%)

22-45

7 (46.7%)

3 (20.0%)

7 (46.7%)

46-65

6 (40.0%)

9 (60%)

5 (33.3%)

66+

5 (33.3%)

3 (20.0%)

3 (20.0%)

Female

11 (73.3%)

11 (73.3%)

11 (73.3%)

Male

4 (26.7%)

4 (26.7%)

4 (26.7%)

Caucasian

11 (73.3%)

11 (73.3%)

11 (73.3%)

African American

4 (26.7%)

4 (26.7%)

4 (26.7%)

Moderate

2 (13.3%)

3 (20.0%)

2 (13.3%)

Severe

4 (26.7%)

4 (26.7%)

4 (26.7%)

Profound

9 (60.0%)

7 (46.7%)

9 (60.0%)

Unspecified

0 (0%)

1 (6.7%)

0 (0%)

Gender

Race

Level of ID

______________________________________________________________________________
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Of the 30 participants with ID and a diagnosis of epilepsy (AED and non-AED group),
there were four seizure types noted in this sample. The majority of the participants had
generalized epilepsy (n = 18), eight had partial epilepsy (v = 3), five out of those eight evolving
into secondary generalized seizures (n = 5), and Epilepsy NOS (n = 4).
Differences in medication may have an impact on the presence and severity of symptoms.
Current medications were noted during the participant’s chart review. All participants in the
AED and control group were on medications. In the AED group, it was found that 73.3% were
on one AED, while 20% were taking two AEDs, and 6.7% were taking three AEDs. In the nonAED group, none of the participants were taking psychotropic medications. In the control group,
the majority of participants (93.3%) were only on one psychotropic medication, while only one
participant was on two (6.7%).
Games-Howell post hoc analyses were employed because equal variances were not
assumed between groups (Hinkle, Wiersma, & Jurs, 1998). According to the post hoc analyses,
no significant differences between the three groups on age, visual impairments, hearing
impairments, and verbal ability (verbal or non- verbal) were identified. Seizure type between the
AED group and non-AED did not significantly differ. However, significant differences were
found in ambulation and medication usage among the three groups. That is, significantly more
participants in the control group were ambulatory (93.3%) than in the AED group (46.7%), F(2,
42) = 5.15, p = .014. In addition, a significant difference was found in medication usage among
the three groups, F(2, 42) = 21.10, p = .00. That is, significantly more participants in the AED
group (p = .00) and control group (p = .00) were taking medications than the non-AED group (p
= .00). However, differences in the amount of medication taken between the AED group and
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control group was non-significant (p = .29). Table 7 shows the frequency of medication usage
among the three groups at the time of the chart review.
Table 7
Medication Usage of the Groups
_____________________________________________________________________________________________

Medication Class

Frequency of Usage
AED
(n = 15)

Non-AED
(n = 15)

Control
(n = 15)

Carbamazepine

2

0

0

Diastat

2

0

0

Phenytoin

5

0

0

Valproic Acid

4

0

0

Lamotrigine

5

0

0

Zonisamide

1

0

0

Aripiprazole

0

0

3

Olanzapine

0

0

5

Quitiapine

0

0

2

Risperidone

0

0

4

Thioridazine

0

0

1

Classic AEDs

Newer AEDs

Anti-psychotics

Anxiolitic
Propanolol
0
0
1
______________________________________________________________________________
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Measures
The SEIZES-B, as previously discussed in Study One, is a 52-item informant based scale
developed for use with adults with ID and epilepsy.
Procedure
The SEIZES-B was administered to direct-care staff members that had known the
participant for a minimum of six months prior to the study. A bachelors-level clinical psychology
graduate student served as the interviewer. Information from the first four subscales of the
SEIZES-B in the AED group was collected from the individual’s chart or medical records by the
interviewer. However, this information was not utilized in the comparison. Interviews were
conducted in accordance with the SEIZES-B manual specifications. All data was collected in the
same two-month period to prevent confounding effects of time.
Following the comparison of the three groups on SE profiles, a series of item correlation
coefficients were conducted for the following ten subscales from the SEIZES-B: 1) Respiratory
Disturbance, 2) Gastric Disturbance, 3) Dermatological Disturbance, 4) Hair Changes, 5) Gait
Disturbance, 6) Tremor, 7) Sedation, 8) Affective Disturbances, and 9) Cognitive Disturbance,
and, 10) Drug-Related Dizziness.
Results
Total scores derived from the SEIZES-B were analyzed across the three diagnostic
groups (AEDs, non-AEDS, control) using a one-way Analysis of Variance (ANOVA).
Differences across the nine of the ten subscales of the SEIZES-B were all non-significant.
However, a significant difference was found across the Hair Changes subscale F(2, 42) = 3.50, p
= .03. With Games-Howell post hoc analyses, no significant difference was found between the
AED group and control group (p = .18). Results are displayed in Table 8.
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Table 8
Means, Standard Deviations, and ANOVA for SEIZES-B Subscale Totals
______________________________________________________________________________
AED

Non-AED

Control

ANOVA

SD
M
SD
M
SD
F(2,42) p
Variable
M
______________________________________________________________________________
Respiratory Disturbance

.33

.90

.00

.00

.00

.00

2.05

.14

Gastric Disturbance

.40

.91

.27

.79

.00

.00

1.27

.29

Dermatological Disturbance

.33

.61

.40

.63

.21

.41

.49

.61

Hair Changes

.60

1.24

.00

.00

.00

.00

3.50

.03*

Gait Disturbance

.40

.91

.13

.51

.20

.41

.68

.51

Tremor

.13

.35

.00

.00

.00

.00

2.15

.12

Sedation

.27

.70

.27

.70

.13

.51

.21

.81

Affective Disturbance

.20

.56

.13

.51

.20

.56

.07

.92

Cognitive Disturbance

.00

.00

.07

.25

.13

.51

.60

.55

Drug-Related Dizziness

.07

.2 5

.00

.00

.00

.00

1.00

.37

*p < .05

After comparing the total subscale scores of the SEIZES-B across the three groups, item
correlation coefficients were calculated using a matrix of Pearson product-moment correlation
coefficient. Each item within the ten subscales of the SEIZES-B was compared across the three
groups. Since this analysis was exploratory in nature, a two-tailed test of significance was set
because the direction of the relationship was unknown. Based on this analysis, six of the ten
subscales contained items that were significant in the AED group.
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In the AED group, very high positive correlations were observed for vomiting shortly
after medication is given and unsteady wide based gait, r = 1.0, p<.01, vomiting shortly after
medication is given and transient dizziness, r = 1.0, p<.01, vomiting throughout the day and
transient dizziness, r = 1.0, p<.01, can only walk with assistance and some mood change; no
interference with daily activities, r = 1.0, p<.01, and mood changes, interference with some
activities and unsteady wide based gait, r = 1.0, p<.01. In addition, the non-AED group had
moderate to very high positive correlations. The control group had two moderately high
correlation coefficients. Overall, the majority of the correlation coefficients were in the low to
moderate range. Only significant correlations and are presented in Table 9.
Table 9
Pearson Product-Moment Correlation Coefficient for SEIZES-B Items Across Groups
______________________________________________________________________________
Subscale and Item
Item
r
______________________________________________________________________________
AED Group
Respiratory Disturbances
Shortness of breath

Slow, unsteady gait

.48**

Labored Breathing

Intermittent tremor

.63**

Vomiting shortly after
medication is given

Unsteady, wide based gait

1.0**

Vomiting shortly after
medication is given

Intermittent tremor

.68**

Vomiting shortly after
medication is given

Some mood changes;
no interference with tasks

.68**

Gastric Disturbances

(table continued)
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(table continued)
Vomiting shortly after

Transient dizziness

1.0**

Vomiting throughout
the day

Transient dizziness

1.0**

Vomiting throughout
the day

Skin sensitive to light

.68**

Vomiting throughout
the day

Hard to awaken, occasionally
sleeps during the day

.68**

Rash consisting of red
discolored patches

Hard to awaken, occasionally
sleeps during the day

.65**

Rash consisting of red
discolored patches

Difficult to stay awake
especially during the day

.68**

Can only walk with
assistance

Mood changes; interfere
with some daily activities

1.0**

Intermittent Tremor

Unsteady wide based gait

.68**

Intermittent Tremor

Transient dizziness

.68**

Frequent or constant tremor

Hard to awaken, occasionally
sleeps during the day

.68**

Some mood changes;
no interference with activities

Unsteady wide based gait

.68**

Some mood changes;
no interference with activities

Transient dizziness

.68**

medication is given

Dermatological Disturbance

Gait Disturbances

Tremor

Sedation

(table continued)
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(table continued)
Mood changes; interference
with some activities

Unsteady wide based gait

1.0**

Gastric distress as evidenced
by doubling over

.68**

Vomiting throughout
the day

Rash consisting of red
discolored patches

.62**

Vomiting throughout
the day

Difficult to stay awake
especially during the day

.68**

Unsteady wide based gait

.68**

Some mood changes; no
interference with activities

Rash consisting of red
discolored patches

.68**

Mood changes; interference
with some activities

Rash consisting of red
discolored patches

.68**

Rash consisting of red
discolored patches

.68**

Mood changes interference
with some activities

1.0**

Non-AED Group
Dermatological Disturbance
Skin sensitive to light as
evidenced by burning easily
Gastric Disturbances

Dermatological Disturbance
Rash consisting of red
discolored patches
Affective Disturbance

Cognitive Disturbance
Decline in attention or
concentration but doesn’t interfere
Gait Disturbances
Unsteady wide based gait

(table continued)
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(table continued)
Unsteady wide-based gait

Decline in attention or
1.0*
Concentration but doesn’t interfere

Sedation
Difficult to stay awake
especially during the day

Some mood change; no
interference with activities

1.0*

Difficult to stay awake
especially during the day

Frequent tremor

.68**

Skin sensitive to light

.54*

Control Group
Sedation
Difficult to stay awake
especially during the day
Affective Disturbance
Mood changes inferences with
Marked impairment of activities
.68**
some activities
significant confusion
_____________________________________________________________________________
** p < .01
* p < .05
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GENERAL DISCUSSION
The purpose of the present study was two-fold. In Study One, the psychometric
properties of the SEIZES-B were investigated. This was achieved by evaluating the interrater
reliability of direct observations using the PDC Nursing Assessment Form. Direct observations
were completed by two informants, a registered nurse and licensed epileptologist. This
comparison was examined to determine if the nurse and epileptologist’s ratings were consistent.
Then, the convergent validity of the SEIZES-B was examined. The SEIZES-B was compared to
direct observations of individuals at the PDC neurology clinic using the Nursing Assessment
Form. In Study Two, differences in the baseline level of SE profiles were evaluated in three
groups with individuals with ID. These three groups were comprised of individuals with epilepsy
taking AEDs, individuals with a diagnosis of epilepsy not taking AEDs, and individuals without
epilepsy taking antipsychotic medications.
Assessing the interrater reliability of the direct observation was first examined. This step
was chosen to demonstrate the consistency and dependability of the instrument (Mitchell, 1979).
Overall, the level of agreement for the majority of the items reflected low positive correlations.
They ranged from poor for Intermittent Tremor (κ = -0.06), to fair for Alert/Awake (κ = 0.53) at
the p<.05 level. For the remaining items, all other correlations were considered poor.
Although the direct observational data did not reveal statistical significance, the Nursing
Assessment Form has clinical utility because any symptom endorsement (e.g., tremor, sedation)
alerts the PDC medical staff that monitoring symptoms in an individual may be necessary and
that medication changes may be appropriate. While it was expected that interrater reliability
would be high between the nurse and epileptologist, given their level of education and
experience, it is unclear why concordance rates were not higher.
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However, before the study began, there was initial resistance from the epileptologist to
complete direct observation ratings. The epileptologist posited time as a factor. In the research
literature, it has been recognized that physicians often lack the time or motivation to accurately
complete rating forms (e.g., symptom checklist, surveys, and questionnaires) (Chappell &
Smithson, 1997). For example, Traynor and his colleagues (1993) found that researchers’ request
for physicians to assist in completing surveys was considered an additional demand placed on
their already busy lives. In addition, Thom, Lee, Dhillon, Dunne, and Plant (2000) found that
physicians sited lack of interest in epilepsy as reasons for declining to participate in research.
Perhaps the lack of concordance between the two observers occurred because of differences in
temperament or differences among interpretations of items on the Nursing Assessment Form.
The second goal of Study One was to examine the convergent validity of the SEIZES-B
by comparing the SEIZES-B to direct observations using the Nursing Assessment Form. An
extensive review of the literature revealed a lack of standardized measures of assessing SE in the
institutionalized ID population. However, interrater reliability (r = .72) and test-retest reliability
(r = .63) using direct care staff as informants demonstrated moderately high reliability
coefficients. According to Campbell and Fiske (1959), both reliability and validity concepts
require that agreement between measures be demonstrated. Thus, it was essential that the
comparison measure for the SEIZES-B items was based on observable data and was verified
with interrater reliability. This comparison provided an estimate of convergent validity to show
that the instrument accurately measured SE of AEDs. It was hypothesized that the SEIZES-B
would have good convergent validity with the epileptologist’s ratings from the Nursing
Assessment Form because both instruments purported to measure similar constructs, and was
designed specifically for individuals with ID and epilepsy.
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The results revealed a statistically significant high positive correlation between the
SEIZES-B and direct observation for Gait Disturbance, r = .97, p<.001. According to Cicchetti
(1994), .97 is classified as an excellent level of clinical significance. In addition, a statistically
low positive correlation was found for Sedation, r = .26, p<.05. However, the range of reliability
coefficients for the remaining items was -.02 to .21. Furthermore, a floor effect observed for the
following domains: Respiratory Disturbance, Hair Changes, Tremor, and Drug-Related
Dizziness.
Several possible reasons why concordance was poor across the two instruments are
offered. First, education level and training between direct-care staff in residential facilities may
differ significantly. As a result, some individuals may lack training to delineate possible
symptoms of drug SE from comorbid medical conditions (e.g., cerebral palsy, movement
disorders, etc.). It is also possible that direct care staff lack understanding of the specific
construct being measured despite efforts of scale developers to eliminate unclear questions
(Cronbach & Meehl, 1955; DeVellis, 1991). However, given the importance of this topic,
education and training direct care staff to detect SE symptoms may be warranted and may help
them to detect SE symptoms.
The lack of convergence between direct care staff and the direct observation question the
appropriateness of the SEIZES-B when direct care staff is used as raters. According to Mitchell
(1979), although indirect measures can yield valuable information, they are usually not as
reliable as direct observation measures.
Another possible reason for the low convergence may be related to different
administration times of the two instruments. Although the SEIZES-B was administered one-totwo weeks after participants attended neurology clinic to prevent confounding effects of time,
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certain behaviors (e.g., vomiting shortly after medication is given) may have occurred in one
setting (e.g., home) and not the other (e.g., neurology clinic). Due to shift changes and
designated appointments times at clinic, direct care staff and medical staff may not witness a
phenomenon and would be subsequently unable to endorse an item on either instrument.
Despite the overall lack of convergence of the SEIZES-B and direct observation, gait
disturbance and sedation are consistently identified in the literature as common SE of AEDs
(Harbord, 2000; Kustra et al., 2005; Stefan & Feuerstein, in press). While the interrater reliability
for Gait Disturbance on the Nursing Assessment Form was r = .33, high convergence of this
subscale on the SEIZES-B suggests its usefulness in identifying possible SE in combination with
direct observations.
The second objective of the present study was to examine group differences of SE
profiles in three groups. In Study Two, 15 participants were compared across three groups (AED,
non-AED use, and control) on SE profiles of the SEIZES-B. Group membership was the
independent variable and SEIZES-B total scores served as the dependent variable. A total of 45
participants were included in this study. A chi-square analysis and ANOVA revealed that the
groups did not differ significantly on the variables of age, gender, level of ID, seizure type, and
medication type.
A one-way ANOVA revealed a statistically significant difference on the Hair Changes
subscale. However, no other statistical differences were found. A floor effect was observed for
the non-AED group and control group on the following subscales: Respiratory Disturbance, Hair
Changes, Tremor, and Drug-Related Dizziness. Games-Howell post hoc analysis was conducted
for Hair Changes. This statistic was chosen because the homogeneity of variance assumption had
been violated (Hinkle, Wiersma, & Jurs, 1998). However, no significant difference was detected
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between the AED group and control group (p = .18). In the medical literature, hirsutism has been
observed as a SE of phenytoin use (Buchanan, 1992; Pellock, 2002). Additionally, alopecia has
been observed as a SE of valproic acid use (Buchanan, 1992; Gates, 2000). Despite the fact that
the data did not reveal statistically significant differences, the endorsement of one SE symptom
may provide useful in making recommendations for titration, alternative drug usage, or
discontinuance.
In Study Two, since the sample consisted of a small number of participants in each group
and a floor effect was observed, a power analysis was conducted to determine whether possible
non-significance findings may have contributed to low power. It was determined a sample of 158
participants would be optimal to achieve a power of .80, using a medium effect size (.05).
Although a much larger sample size would have been ideal, it was impossible to attain due to
exclusionary criteria and matching practices utilized in this study. Regardless, a larger sample
may have lead to the detection of more significant differences across the groups.
Lastly, a series of individual item correlations were examined in order to examine if there
was a relationship between certain SE symptoms across the three groups. Based on the analyses,
all three groups showed low to very high positive correlations among certain items. Because the
ten subscales of the SEIZES-B contained heterogeneous symptoms, low-to-high correlations
were not expected. Several subscales, (e.g., Gastric Disturbance, Gait Disturbance, and Sedation)
showed perfect positive correlations with other constructs. The relationship between these
various constructs warrants a more thorough investigation of these symptoms before making any
meaningful interpretation of the endorsed symptom.
The results of the current study extended research on SE of AEDs in the institutionalized
ID population. This study represents the first to examine the convergent validity of the SEIZES-
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B and interrater reliability of direct observations. While the individual interrater reliability
coefficient for Gait Disturbance on the SEIZES-B is considered high by research and clinical
standards (Cicchetti, 1994; Mitchell, 1979), the convergent validity of the SEIZES-B and direct
observation were poor. Although it is disappointing that the current study did not establish
overall high reliability or convergent validity, the psychometric properties of the two instruments
provided information that was previously unavailable.
Even though no statistical differences were detected across groups on SE profiles, subtle
differences in symptomatology are still a major issue in seizure management. As stated earlier, in
individuals with ID, assessments and monitoring of SE are based on informant-based rating
scales, changes in observable behaviors, and laboratory monitoring. Based on the results of this
study, it is clear that informant-based ratings scales and direct observation alone cannot replace
current assessment and management practices.
Continued efforts are being made to improve the pharmacological properties of available
AEDs by developing newer AEDs with fewer interactions and untoward SE (Brodie, 1995). For
example, pregabalin is a novel AED used for neuropathic pain, as an adjunct therapy for partial
seizures, and in generalized anxiety disorder (Hamandi & Sander, 2006). It was designed as a
more potent successor to gabapentin (Sills, 2006), and received U.S. Food and Drug
Administration approval for use in treating epilepsy, diabetic neuropathy pain and post-herpetic
neuralgia pain in June 2005 (Hamandi & Sander, 2006). In Study One, 13 (17.8%) participants
were taking pregabalin at the time of chart review. Stefan and Feurstein (in press) found that the
most frequent side effects of pregabalin in controlled studies were dizziness, somnolence, ataxia,
and weight gain. To date, no research has been conducted to assess the SE of pregabalin in the
institutionalized ID population. Future research in this area is warranted.
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Similar to that of pharmacological interventions for individuals with epilepsy, treatment
of individuals with psychopathology (e.g., bipolar disorder) usually includes a drug regimen.
According to Matson, González, Smith, Terlonge, Thorson, and Dixon (2006), who conducted a
20-year review of the literature, SE of pharmacotherapy treatment often include parkinsonism,
tardive dyskinesia, akathesia, dystonia, and tremor. Elsewhere in the literature, it has been well
documented that antipsychotic medications are not free from untoward SE in the institutionalized
ID population (Lipman, 1970). Therefore, it is unlikely that all of the participants in the control
group were free from experiencing untoward SE. An explanation for the floor effect observed in
the non-AED group and control group could be that direct care staff could not consistently
identify or recall when symptoms occurred. However, the lack of identified symptoms may have
been compromised by true or random error (Murphy & Davidshofer, 2001).
In the field of ID, treatment of epilepsy and identification and monitoring of SE has been
proven difficult. Potential differences in observers, direct care staff, limitations of participant
self-report, and methodological constraints, contribute to the complexity of assessment,
monitoring, and research investigating drug SE in institutionalized ID populations (Matson,
Bielecki, Mayville, & Matson, 2003). Nevertheless, it behooves us to continue focusing on adults
with ID and epilepsy and to study, develop, and improve assessment and monitoring techniques
of SE. Our ability to improve the psychometrics of SE instruments may improve the quality of
life in individuals with ID.
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